Skip to Content

'
Paul M. Cinciripini, Ph.D.

Present Title & Affiliation

Primary Appointment

Department Chair ad interim, Department of Behavioral Science, Division of OVP, Cancer Prevention and Population Sciences, University of Texas MD Anderson Cancer Center, Houston, TX
Director, Tobacco Treatment Program, Department of Behavioral Science, Division of OVP, Cancer Prevention and Population Sciences, University of Texas MD Anderson Cancer Center, Houston, TX
Professor w/Tenure, Department of Behavioral Science, Division of OVP, Cancer Prevention and Population Sciences, University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Adjunct Professor, Department of Psychology, University of Houston, Houston, TX
Adjunct Professor, Department of Behavioral Science, UT School of Public Health, Houston, TX
Adjunct Professor, Department of Psychiatry, Baylor College of Medicine Psychiatry & Behavioral Sciences, Houston, TX

Bio Statement

 I serve as Professor and Chair ad interim for the Department of Behavioral Science, and I am the Director of the Tobacco Treatment Program at UT MD Anderson Cancer Center. I have over 30 years of experience conducting basic and clinical research in the area of smoking cessation and nicotine psychopharmacology. My major research interests includes studies developing novel behavioral and pharmacological treatments for nicotine dependence, and those that study individual differences associated with treatment outcome.  In particular, my work in this area has focused on psychological (negative affect, coping self-efficacy ), psychophysiological  (emotional reactivity), neural (EEG/fMRI) and genetic predictors of treatment outcome (pharmacogenetics). In addition to community based samples my work has also involved  populations with psychiatric and medical co-morbidities including depression, pregnancy and cancer. I have authored over 190 articles and book chapters, conducted over 20 NIH- and other-sponsored randomized clinical trials examining behavioral and pharmacological interventions for smoking cessation, and served as a senior co-investigator on over 20 NIH sponsored trials, and mentored 20 junior scientists. I am presently the PI or site PI on five active NIH-funded studies. 

 

Research Interests

Paul M. Cinciripini, Ph.D. is Professor and Chair ad interim of the Department of Behavioral Science and Director of the Tobacco Treatment Program at the University of Texas MD Anderson Cancer Center. He has over 30 years of experience conducting basic and clinical research in the area of smoking cessation and nicotine psychopharmacology.   Dr. Cinciripini has been the recipient of several NIH-, extramural- and industry-sponsored research grants and is the author of over 190 articles and book chapters. Dr. Cinciripini’s major research includes studies of nicotine titration and compensation, psychophysiological effects of nicotine during stress, individual differences in the effects of nicotine on EEG and cardiovascular activity, genetic factors treatment outcome, pharmacogenetic effects of antidepressants during smoking cessation, and recent studies using startle probe and EEG/ERP methodology to examine the relations between genetics, emotional reactivity, nicotine exposure and nicotine withdrawal. He has also studied the effects of depression, coping behavior, and self-efficacy as well as genetic factors related to nicotine dependence and tested novel behavioral and pharmacological approaches for treatment. Examples of his work in this latter area include: the development of a “scheduled smoking” procedure and a recent application of this technology for delivery on a handheld computer; development of a smoking cessation video series for pregnant smokers; evaluating combination therapies using nicotine replacement, behavioral counseling, and other approaches; and testing novel pharmacological compounds, including anxiolytics, antidepressants, nicotine partial agonists, and cannabinoid antagonists. He is presently the PI on several NIH-funded clinical trials, including, “Evaluating New Nicotine Standards for Cigarettes  (CENIC),” which addresses the best approach to reducing nicotine in cigarettes by comparing a gradual vs. immediate reduction to low levels of nicotine; and  “Pharmacogenetics of Nicotine Addiction Treatment (PNAT),” which optimizes pharmacotherapeutic choices for individuals who wish to quit smoking. 

Education & Training

Degree-Granting Education

1978 Auburn University, Auburn, AL, PHD, Cum Laude, Clinical Psychology
1976 Auburn University, Auburn, AL, MS, Clinical Psychology
1974 Pennsylvania State University, State College, PA, BS, Psychology

Postgraduate Training

1977-1978 Clinical Residency, Clinical Psychology, Western Psychiatric Institute and Clinic, The University of Pittsburgh School of Medicine, Pittsburgh, PA

Board Certifications

1996 American Psychological Association Division 38
1993 American Board of Professional Psychology
1989 American Board of Behavioral Psychology
1983 Texas State Board of Examiners in Psychology

Experience/Service

Academic Appointments

Associate Professor w/Tenure, Department of Behavioral Science, Division of OVP, Cancer Prevention and Population Sciences, University of Texas M. D. Anderson Cancer Center, Houston, TX, 10/1994-9/2001
Associate Professor w/Tenure, Department of Psychiatry, University of Texas Medical Branch, Galveston, TX, 1988-1994
Assistant Professor, Department of Psychiatry, University of Texas Medical Branch, Galveston, TX, 1983-1988
Assistant Professor, Physiology & Behavioral Science, Minnesota School of Medicine, Duluth, MN, 1978-1983

Institutional Committee Activities

Chair, Search Committee: Section Chief of Behavioral Statistics, 2/2010-9/2012
Member, OVP Capital Equipment - Faculty Ranking Committee, 2/2009-present
Member, American Cancer Society Institutional Research Grant Review Committee, 1/2008-1/2011
Member, Department of Epidemiology Chair Search Committee, 2008-9/2010

Selected Publications

Peer-Reviewed Original Research Articles

1. Cui Y, Robinson JD, Engelmann JM, Lam CY, Minnix JA, Karam-Hage M, Wetter DW, Dani JA, Kosten TR, Cinciripini PM. Reinforcement Sensitivity Underlying Treatment-Seeking Smokers' Affect, Smoking Reinforcement Motives, and Affective Responses. Psychol Addict Behav 29(2):300-11, 6/2015. e-Pub 1/2015. PMCID: PMC4469611.
2. Aigner CJ, Cinciripini PM, Anderson KO, Baum GP, Gritz ER, Lam CY. The Association of pain with smoking and quit attempts in an electronic diary study of cancer patients trying to quit. Nicotine Tob Res. e-Pub 6/2015. PMID: 26038362.
3. Wippold R, Karam-Hage M, Blalock J, Cinciripini P. Selection of optimal tobacco cessation medication treatment in cancer patients. Clin J Oncol Nurs 19(2):170-5, 4/2015. PMID: 25840382.
4. Adams CE, Cano MA, Heppner WL, Stewart DW, Fernandez VC, Vidrine JI, Li Y, Cinciripini PM, Ahluwalia JS, Wetter DW. Testing a moderated mediation model of mindfulness, psychosocial stress, and alcohol use among African American smokers. Mindfulness 6(2):315-325, 4/2015. e-Pub 11/2013. PMCID: PMC4384702.
5. Meyer MJ, Coull BA, Versace F, Cinciripini P, Morris JS. Bayesian function-on-function regression for multilevel functional data. Biometrics. e-Pub 3/2015. PMID: 25787146.
6. Gu X, Lohrenz T, Salas R, Baldwin PR, Soltani A, Kirk U, Cinciripini PM, Montague PR. Belief about nicotine selectively modulates value and reward prediction error signals in smokers. Proc Natl Acad Sci U S A 112(8):2539-44, 2/2015. e-Pub 1/2015. PMCID: PMC4345562.
7. Lin J, Blalock JA, Chen M, Ye Y, Gu J, Cohen L, Cinciripini PM, Wu X. Depressive symptoms and short telomere length are associated with increased mortality in bladder cancer patients. Cancer Epidemiol Biomarkers Prev 24(2):336-43, 2/2015. e-Pub 11/2014. PMCID: PMC4332382.
8. Robinson JD, Versace F, Engelmann JM, Cui Y, Slapin A, Oum R, Cinciripini PM. The motivational salience of cigarette-related stimuli among former, never, and current smokers. Exp Clin Psychopharmacol 23(1):37-48, 2/2015. e-Pub 12/2014. PMCID: PMC4314387.
9. Lerman C, Schnoll RA, Hawk LW, Cinciripini PM, George TP, Wileyto EP, Swan GE, Benowitz N, Heitjan DF, Tyndale RF, Leone F, Glick HA, Pinto A, Sanborn PM, Gariti P, Landis JR, Novalen M, Aziziyeh A, Mahoney M, Karam-Hage M, Conti DV, Bergen A. A Randomized Placebo-controlled Trial to Test a Genetically-informed Biomarker for Personalizing Treatment for Tobacco Dependence. Lancet Respir Med pii: S2213-2600(14). e-Pub 1/2015.
10. Parrott CE, Rathnayaka N, Blalock JA, Minnix JA, Cinciripini PM, Vincent JP, Wetter DW, Green C. Examination of the Wisconsin Inventory of Smoking Dependence Motives (WISDM-68) factor structure in a sample of pregnant smokers. Nicotine Tob Res. e-Pub 12/2014. PMID: 25475086.
11. Chenoweth MJ, Novalen M, Hawk LW, Schnoll RA, George TP, Cinciripini PM, Lerman C, Tyndale RF. Known and Novel Sources of Variability in the Nicotine Metabolite Ratio in a Large Sample of Treatment-Seeking Smokers. Cancer Epidemiol Biomarkers Prev 23(9):1773-82, 9/2014. e-Pub 7/2014. PMCID: PMC4154993.
12. Robinson JD, Engelmann JM, Cui Y, Versace F, Waters AJ, Gilbert DG, Gritz ER, Cinciripini PM. The effects of nicotine dose expectancy and motivationally relevant distracters on vigilance. Psychol Addict Behav 28(3):752-760, 9/2014. e-Pub 5/2014. PMID: 24841184.
13. Stotts AL, Northrup TF, Cinciripini PM, Minnix JA, Blalock JA, Mullen PD, Pedroza C, Blackwell S. A Randomized, Controlled Pilot Trial of Bupropion for Pregnant Smokers: Challlenges and Future Directions. Am J Perinatol. e-Pub 8/2014. PMID: 25111040.
14. Cano MÁ, Lam CY, Chen M, Adams CE, Correa-Fernández V, Stewart DW, McClure JB, Cinciripini PM, Wetter DW. Positive smoking outcome expectancies mediate the association between negative affect and smoking urge among women during a quit attempt. Exp Clin Psychopharmacol 22(4):332-40, 8/2014. e-Pub 5/2014. PMCID: PMC4115029.
15. Ostroff JS, Burkhalter JE, Cinciripini PM, Li Y, Shiyko MP, Lam CY, Hay JL, Dhingra LK, Lord-Bessen J, Holland SM, Manna R. Randomized trial of a pre-surgical scheduled reduced smoking intervention for patients newly diagnosed with cancer. Health Psychol 33(7):737-747, 7/2014. e-Pub 7/2013. PMCID: PMC4116187.
16. Karam-Hage M, Cinciripini PM, Gritz ER. Tobacco use and cessation for cancer survivors: An overview for clinicians. CA Cancer J Clin 64(4):272-90, Jul-Aug, 7/2014. e-Pub 5/2014. PMCID: PMC4377321.
17. Adams CE, Chen M, Guo L, Lam CY, Stewart DW, Correa-Fernández V, Cano MA, Heppner WL, Vidrine JI, Li Y, Ahluwalia JS, Cinciripini PM, Wetter DW. Mindfulness Predicts Lower Affective Volatility among African Americans During Smoking Cessation. Psychol Addict Behav 28(2):580-585, 6/2014. e-Pub 6/2014. PMCID: PMC4096677.
18. Versace F, Engelmann JM, Robinson JD, Jackson EF, Green CE, Lam CY, Minnix JA, Karam-Hage MA, Brown VL, Wetter DW, Cinciripini PM. Prequit fMRI Responses to Pleasant and Cigarette Cues Predict Smoking Cessation Outcome. Nicotine Tob Res 16(6):697-708, 6/2014. e-Pub 12/2013. PMCID: PMC4015090.
19. Schnoll RA, George T, Hawk L, Cinciripini P, Wileyto P, Tyndale RF. The relationship between nicotine metabolite ratio and three self-report measures of nicotine dependence across sex and race. Psychopharmacology 231(12):2515-2523, 6/2014. e-Pub 1/2014. PMCID: PMC4040302.
20. Waters AJ, Szeto EH, Wetter DW, Cinciripini PM, Robinson JD, Li Y. Cognition and Craving During Smoking Cessation: An Ecological Momentary Assessment Study. Nicotine Tob Res 16 Suppl 2:S111-8, 5/2014. e-Pub 7/30/2013. PMCID: PMC3977632.
21. Volk RJ, Linder SK, Leal VB, Rabius V, Cinciripini PM, Kamath GR, Munden RF, Bevers TB. Feasibility of a patient decision aid about lung cancer screening with low-dose computed tomography. Prev Med 62C:60-63, 5/2014. e-Pub 2/8/2014. PMID: 24518006.
22. Lam CY, Businelle MS, Aigner CJ, McClure JB, Cofta-Woerpel L, Cinciripini PM, Wetter DW. Individual and Combined Effects of Multiple High-Risk Triggers on Postcessation Smoking Urge and Lapse. Nicotine Tob Res 16(5):569-575, 5/2014. e-Pub 12/9/2013. PMCID: PMC3977487.
23. Lam CY, Businelle MS, Cofta-Woerpel L, McClure JB, Cinciripini PM, Wetter DW. Positive smoking outcome expectancies mediate the relation between alcohol consumption and smoking urge among women during a quit attempt. Psychol Addict Behav 28(1):163-172, 3/2014. e-Pub 3/2014. PMID: 24731113.
24. Kendzor DE, Businelle MS, Reitzel LR, Castro Y, Vidrine JI, Mazas CA, Cinciripini PM, Lam CY, Adams CE, Correa-Fernández V, Cano MÁ, Wetter DW. The Influence of Discrimination on Smoking Cessation among Latinos. Drug Alcohol Depend 136:143-148, 3/2014. e-Pub 1/2014. PMCID: PMC3967740.
25. Rabius V, Karam-Hage M, Blalock JA, Cinciripini PM. "Meaningful use" provides a meaningful opportunity. Cancer 120(4):464-468, 2/2014. e-Pub 10/2013. PMCID: PMC4054930.
26. Vidrine JI, Businelle MB, Reitzel LR, Cao Y, Cinciripini PM, Marcus MT, Li Y, Wetter DW. Coping Mediates the Association of Mindfulness with Psychological Stress, Affect and Depression Among Smokers Preparing to Quit. Mindfulness. e-Pub 1/2014.
27. Chiang S, Guindani M, Versace F, Engelmann J, Cinciripini P, Vannuci M. A hierarchal bayesian mixture model for the identification of fMRI biomarkers associated to the prediction of smoking cessation outcomes. J Am Stat Assoc. Submitted.
28. Chenoweth MJ, Schnoll RA, Novalen M, Hawk Jr. LW, George TP, Cinciripini PM, Lerman C, Tyndale RF. "Association between the nicotine metabolite ratio and one-week smoking abstinence is not affected by factors that influence the nicotine metabolite ratio. Nicotine Tob Res. Submitted.
29. Cinciripini PM, Green CE, Robinson JD, Karam-Hage M, Engelmann J, Minnix J, Wetter D, Versace F. Benefits of varenicline vs. bupropion for smoking cessation among those with high cigarette reward sensitivity. Nicotine Tob Res. Submitted.
30. Hay, JL, Lord-Bessen J, Yuelin L, Burkhalter J, Cinciripini PM, Dhingra LK, Holland S, Ostroff J. Smoking status and changes in cancer patients' risk perception and worry. J Health Psychol. Submitted.

Invited Articles

1. Karam-Hage M, Minnix J, Cinciripini P, Gritz E. Alcohol and smoking cessation for cancer survivors. In: UpToDate. UpToDate, 1/2015.
2. Cinciripini PM, Karam-Hage M. Study suggests varenicline safe and effective among adults with stable depression. Evid Based Med 19(3):92, 6/2014. e-Pub 1/2014. PMID: 24482150.

Abstracts

1. Karam MH, Robinson JD, Sharma M, Blalock J, Rabius V, Cinciripini P. Bupropion XL has the same effectiveness and similar side effect profile as Bupropion Sr when used for Smoking Cessation among Cancer Patients. 2014 Society for Research on Nicotine and Tobacco, Seattle, Washington, 2/2014.
2. Northrup TF, Blackwell SC, Hutchinson MS, Blalock J, Minnix J, Mullen PD, Pedroza C, Mulpur S, Cinciripini P, Stotts AL. Challenges in Recruitment for a Phase II Trial of Bupropion for Smoking Cessation in Pregnancy. 2014 Society for Research on Nicotine and Tobacco, Seattle, Washington, 2/2014.
3. Rabius V, Cinciripini P. Development and effectiveness of a Multi-layered Tobacco Cessation Program for Cancer Patients. 2014 Society for Research on Nicotine and Tobacco, Seattle, Washington, 2/2014.
4. Blalock JA, Mathew AR, Robinson JD, Brown RA, Karam HM, Cinciripini PM. Evaluation of mediators of an intensive depression-focused intervention for pregnant smokers using mediated moderation analysis. 2014 Society for Research on Nicotine and Tobacco, Seattle, WA, 2/2014.

Book Chapters

1. Karam-Hage M, Cinciripini PM. Tobacco Cessation. In: Advances in Cancer Survivorship Management. MD Anderson Cancer Care Series, First. Ed(s) Buzdar AU, Freeman RS. Springer: New York, 257-274, 2015.
2. Karam-Hage M, Rabius V, Cinciripini PM, Robinson J, Gritz E. Nicotine Dependence: Current Treatments and Future Directions. In: Abeloff's Clinical Oncology, 5th. Ed(s) Niederhuber J, Armitage JO, Doroshow JH, Kastan MB, Tepper JE. Elsevier: Philadelphia, 360-371, 2014.

Grant & Contract Support

Title: Promoting long-term abstinence from smoking among cancer patients
Funding Source: NIH
Role: Principal Investigator
Duration: 4/1/2016 - 3/31/2021
 
Title: The effects of celecoxib on cancer-related fatigue & inflammatory processes
Funding Source: NIH
Role: Principal Investigator
Duration: 4/1/2016 - 3/31/2021
 
Title: Evaluating concomitant use of very low nicotine content cigarettes and e-cigarettes among daily and non-daily smokers
Funding Source: NIH/NIDA
Role: Principal Investigator
Duration: 9/1/2015 - 8/31/2020
 
Title: Resisting or giving in: neurophysiological mechanisms underlying temptations
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Francesco Versace
Duration: 9/1/2015 - 8/31/2020
 
Title: Bayesian methods for complex, high-dimensional functional data in cancer research
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Jeffrey Morris
Duration: 7/1/2015 - 6/30/2020
 
Title: Neurobehavioral assessment of reward sensitivity in young smokers
Funding Source: NIH/NIDA
Role: Co-Investigator
Principal Investigator: Francesco Versace
Duration: 3/31/2015 - 3/30/2017
 
Title: Varenicline and Combined NRT for Initial Smoking Cessation and Rescue Treatment in Smokers: A Randomized Pilot Trial
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 3/1/2015 - 2/28/2018
 
Title: Evaluating New Nicotine Standards for Cigarettes - CENIC Project 2
Funding Source: NIH/NIDA
Role: Principal Investigator-MDACC
Principal Investigator: Eric Donny & Dorothy Hatsugami
Duration: 9/1/2014 - 8/31/2017
 
Title: Intrinsic Reward Sensitivity & Smoking Cessation with Varenicline or Patch NRT
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 9/1/2014 - 8/30/2017
 
Title: Smartphone delivered attentional bias modification training for smokers
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Jason Robinson
Duration: 8/1/2014 - 7/31/2018
 
Title: Promoting Informed Decisions about Lung Cancer Screening
Funding Source: Patient-Centered Outcomes Research Institute
Role: Co-Investigator
Principal Investigator: Robert Volk
Duration: 5/1/2014 - 4/30/2017
 
Title: Neurobiological substrates of imminent smoking: A missing link in cue reactivity
Funding Source: NIH/NIDA
Role: Mentor
Duration: 7/1/2013 - 5/31/2018
 
Title: Using Deep Sequencing Technology to Study Genes & Behavioral Phenotypes Related to Smoking Cessation, Negative affect & Nicotine Withdrawal
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 6/1/2013 - 5/31/2016
 
Title: A Phase 4, non-treatment, follow-up for cardiac assessments following use of smoking cessation treatments in subjects with and without a history of psychiatric disorders, cardiac assessments after treatment
Funding Source: Pfizer Inc.
Role: Principal Investigator
Duration: 3/22/2013 - 3/21/2015
 
Title: Identifying topiramate's therapeutic mechanisms through motivational salience
Funding Source: NIH/NIDA
Role: Co-Investigator
Principal Investigator: Jason Robinson
Duration: 9/1/2012 - 8/31/2017
 
Title: Beyond Cue Reactivity: ERPs, Sensitivity to Natural Rewards and Smoking Cessation
Funding Source: NIH/NIDA
Role: Co-Investigator
Principal Investigator: Francesco Versace
Duration: 7/15/2012 - 6/30/2015
 
Title: A Phase 4, randomized, double-blind, active and placebo-controlled, multicenter study evaluating the neuropsychiatric safety and efficacy of 12 weeks varenicline tartrate 1mg BID for smoking cessation in subjects with and without a history of psychiatric disorder
Funding Source: Pfizer Inc.
Role: Principal Investigator-MDACC
Duration: 8/16/2011 - 8/15/2015
 
Title: Pharmacogenetics of Nicotine Addiction Treatment (PNAT).
Funding Source: NIH/NIDA
Role: Principal Investigator-MDACC
Principal Investigator: Lerman, Caryn (PI) (Cinciripini, Site PI)
Duration: 8/1/2010 - 6/30/2015
 
Title: Role of Habenula in Tobacco Addiction
Funding Source: NIH/NIDA
Role: Mentor
Duration: 8/1/2010 - 12/31/2014
 
Title: New pharmacotherapy for alcohol and co-morbid disorders
Funding Source: NIH/NIAAA
Role: Co-Principal Investigator
Principal Investigator: Cinciripini, P., Alt-Daoud, N., Anthenelli, R.
Duration: 7/1/2010 - 8/31/2015
 
Title: Neurobehavioral metrics for the assessment and treatment of depression
Funding Source: NIH/NIMH
Role: Co-Investigator
Principal Investigator: Chiu
Duration: 7/1/2010 - 1/31/2015
 
Title: A Second Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy, Immunogenicity and Safety of 3'-aminomethylnicotine-P. aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) as an Aid to Smoking Cessation, Protocol
Funding Source: Nabi Biopharmaceuticals
Role: Principal Investigator-MDACC
Duration: 3/24/2010 - 3/31/2014
 
Title: Suppression of Negative Affect Indexed by the Late Positive Potential in Smokers, Protocol
Funding Source: NIH/NIDA
Role: Co-Investigator
Principal Investigator: Minnix, Jennifer
Duration: 5/1/2009 - 4/30/2015
 
Title: Combating Tobacco in the United States Army , Protocol
Funding Source: Department of Defense (DOD)
Role: Co-Investigator
Principal Investigator: Prokhorov
Duration: 4/1/2009 - 4/30/2016
 
Title: Effectiveness of Varenicline plus Bupropion for Smoking Cessation, Protocol
Funding Source: NIH/NIDA
Role: Principal Investigator
Duration: 4/1/2009 - 12/31/2015
 
Title: Ecological Momentary Assessment, Peak-end Rule, and Smoking Relapse., Protocol
Funding Source: American Cancer Society (ACS)
Role: Mentor
Principal Investigator: Lam, Cho
Duration: 1/1/2009 - 12/31/2014

Last updated: 6/24/2015